Our previous work demonstrated that CHI3L1 is implicated in PDAC cellular resistance to gemcitabine, identifying CHI3L1 as a potential therapeutic target for the treatment of this type of cancer [9]. The gene discussed is CHI3L1; the disease is cancer.